Navigation Links
David Norton Appointed to TB Alliance's Board of Directors
Date:3/4/2013

NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to its Board of Directors of David Norton , former Company Group Chairman of Global Pharmaceuticals for Johnson & Johnson (J&J). Mr. Norton brings to TB Alliance nearly 40 years of experience within the pharmaceutical sector, and is noted for his strategy in charting the growth of J&J's pharmaceuticals group.

"Tuberculosis research is on the verge of delivering incredible breakthroughs," said Mr. Norton. "I am committed to leveraging my experience in global product development and commercialization to enhance the impact of such crucial efforts and help stop the TB pandemic."

Throughout his career, Mr. Norton has helped lead J&J's efforts around research and development, commercial operations, licensing, and acquisitions. Now retired, he serves as Chairman of the Board of Directors of the American Foundation for Suicide Prevention. He is a member of the Board of Directors of Savient and recently served as interim CEO. Previously, Mr. Norton served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Alliance for Aging Research.

Dr. Carlos Morel , Chairman of the Board for TB Alliance and Director of the Center for Technological Development in Health (CDTS) of FIOCRUZ, remarked, "Mr. Norton's appointment to the TB Alliance's Board of Directors will expand the organization's knowledge — from developing new TB drug regimens to now ensuring widespread access to them. Mr. Norton's deep experience in shepherding new treatments to global markets will help the TB Alliance achieve its mission."

Tuberculosis (TB) is a global pandemic, killing someone approximately every 25 seconds — nearly 1.4 million in 2011 alone. The WHO estimates that two billion people — one third of the world's population — are infected with Mycobacterium tuberculosis (M.tb), the bacillus that causes the disease. Today's TB drug regimens take too long to cure, are complicated to administer, and can be toxic.  New drug regimens are critical to drastically reduce the global TB burden and to stop the growth and spread of drug-resistant forms of the disease.

About TB Alliance:
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid , UK aid, UNITAID, National Institute of Allergy and Infectious Disease, the United States Agency for International Development, and the United States Food and Drug Administration, and the United States AIDS Clinical Trials Group. For more information, please visit tballiance.org.

Contact:

Joanna Breitstein
TB Alliance
(m) 646.616.8613
Joanna.breitstein@tballiance.org


'/>"/>
SOURCE TB Alliance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. David F. Harty Joins Systech International as Vice President
2. Dr. David Brailer and Stephen Dubner Keynotes for NYeC 2012 Digital Health Conference
3. WebMD Taps David C. Marek to Assume Consumer Leadership Role
4. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
5. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
6. Herb Baer Appointed President of Polar USA
7. New Executive Vice President Commercial Appointed
8. Israel Makov Appointed Chairman of Sun Pharma Board
9. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
10. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- Intec Pharma Ltd. (NASDAQ: ... announced the appointment of Pnina Strauss-Levy as ... Strauss-Levy has 15 years of experience in clinical research ... record, having supported the advancement of several products through ... the United States and ...
(Date:5/3/2016)... , May 3, 2016 ... bekannt, dass sie einen entscheidenden Meilenstein durch ... Ein Aufruf zum Handeln, um Patientenresultate  bei ... trägt zu Fortschritten im Verständnis der Hepatischen ... ein Bewusstsein für Hepatische Enzephalopathie in der ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
Breaking Medicine Technology:
(Date:5/3/2016)... Tysons Corner, VA (PRWEB) , ... May 03, ... ... a leading provider of innovative information technology (IT) solutions and digital consulting services ... its Enterprise Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... solutions, today announced the new SecureAccess feature for its CelestixEdge solution. CelestixEdge ... release will enable organizations to get the DirectAccess user experience on unsupported ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dave Newberry, broker/owner of Newberry Realty, recently ... (PICC) annual fundraiser luncheon on Friday, May 20. “We have raised over $1,000 for ... drug abuse,” said Newberry. , PICC is a local Kent, WA, clinic that cares ...
(Date:5/2/2016)... ... May 02, 2016 , ... Those who may ... can find some useful information in a new video released by Serenity Recovery, ... which can be viewed on the Serenity Recovery YouTube channel, examines various treatment ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... of innovation by partnering with college students at University of Colorado in Boulder ... senior level advertising campaigns class in the School of Journalism, who selected Beanfields ...
Breaking Medicine News(10 mins):